治疗期间体内出现高水平耐药揭示耳念珠菌两性霉素B耐药的首个已鉴定机制
对一例患者来源的四株耳念珠菌进行全基因组测序,并用Cas9介导的基因操作构建突变株进行两性霉素B药敏试验和甾醇谱分析。发现ERG6甾醇甲基转移酶基因的新突变与两性霉素B耐药相关,该突变单独即可导致两性霉素B耐药性增加>32倍。甾醇谱分析显示麦角甾醇生物合成受阻并积累胆甾烷型甾醇,证实ERG6突变为耳念珠菌临床两性霉素B耐药的首个已鉴定机制。
要点
- 耳念珠菌ERG6基因突变与两性霉素B耐药相关,该突变单独即可使耐药性增加>32倍。
- 携带临床来源ERG6突变的分离株和菌株中麦角甾醇生物合成受阻并积累胆甾烷型甾醇。
- 该突变是耳念珠菌临床两性霉素B耐药的首个已鉴定机制。
核心结论
- 耳念珠菌ERG6基因突变被确定为该菌临床两性霉素B耐药的首个已鉴定机制。
研究设计与样本
- 对来自单一患者病例的四株耳念珠菌分离株进行全基因组测序。
- 使用Cas9介导的基因操作生成携带目标突变的突变株,随后进行两性霉素B药敏试验和全面甾醇谱分析。
主要发现
- 耳念珠菌甾醇甲基转移酶基因ERG6的新突变与两性霉素B耐药相关,该突变单独即可导致两性霉素B耐药性增加>32倍。
- 全面甾醇谱分析显示,携带临床来源ERG6突变的分离株和菌株中麦角甾醇生物合成受阻,并相应积累胆甾烷型甾醇。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Candida auris has emerged as a health-care-associated and multidrug-resistant fungal pathogen of great clinical concern. As many as 50% of C. auris clinical isolates are reported to be resistant to amphotericin B, but no mechanisms contributing to this resistance have been identified. Here we describe a clinical case in which high-level amphotericin B resistance was acquired in vivo during therapy and undertake molecular and genetic studies to identify and characterize the genetic determinant of resistance. METHODS: Whole-genome sequencing was performed on four C. auris isolates obtained from a single patient case. Cas9-mediated genetic manipulations were then used to generate mutant strains harbouring mutations of interest, and these strains were subsequently subjected to amphotericin B susceptibility testing and comprehensive sterol profiling. RESULTS: A novel mutation in the C. auris sterol-methyltransferase gene ERG6 was found to be associated with amphotericin B resistance, and this mutation alone conferred a >32-fold increase in amphotericin B resistance. Comprehensive sterol profiling revealed an abrogation of ergosterol biosynthesis and a corresponding accumulation of cholesta-type sterols in isolates and strains harbouring the clinically derived ERG6 mutation. CONCLUSIONS: Together these findings definitively demonstrate mutations in C. auris ERG6 as the first identified mechanism of clinical amphotericin B resistance in C. auris and represent a significant step forward in the understanding of antifungal resistance in this emerging public health threat.
引用
- Rybak JM, Barker KS, Muñoz JF, et al. In vivo emergence of high-level resistance during treatment reveals the first identified mechanism of amphotericin B resistance in Candida auris. Clin Microbiol Infect. 2021. PMID: 34915074. doi:10.1016/j.cmi.2021.11.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。